Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, Swart JF, Wulffraat NM, Dolman KM, Koopman-Keemink Y, Hoppenreijs EP, Armbrust W, ten Cate R, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2013 Sep;52(9):1674-9. doi: 10.1093/rheumatology/ket170. Epub 2013 Jun 4.

PMID:
23740187
2.

Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.

Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.

Rheumatology (Oxford). 2013 Apr;52(4):712-7. doi: 10.1093/rheumatology/kes373. Epub 2012 Dec 24.

PMID:
23267169
3.

Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.

Sevcic K, Orban I, Brodszky V, Bazso A, Balogh Z, Poor G, Kiss E.

Rheumatology (Oxford). 2011 Jul;50(7):1337-40. doi: 10.1093/rheumatology/ker103. Epub 2011 Mar 3.

PMID:
21372001
4.

Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.

Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.

J Rheumatol. 2011 Oct;38(10):2258-63. doi: 10.3899/jrheum.110145. Epub 2011 Aug 15.

PMID:
21844151
5.

Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.

Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.

Ann Rheum Dis. 2013 May;72(5):721-7. doi: 10.1136/annrheumdis-2011-201060. Epub 2012 Jun 23.

PMID:
22730374
6.

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2015 Jul;74(7):1379-86. doi: 10.1136/annrheumdis-2013-204641. Epub 2014 Mar 18.

PMID:
24641940
7.

Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?

Otten MH, Prince FH, Ten Cate R, van Rossum MA, Twilt M, Hoppenreijs EP, Koopman-Keemink Y, Oranje AP, de Waard-van der Spek FB, Gorter SL, Armbrust W, Dolman KM, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2011 Feb;70(2):337-40. doi: 10.1136/ard.2010.135731. Epub 2010 Nov 10.

PMID:
21068101
8.

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.

Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2009 May;68(5):635-41. doi: 10.1136/ard.2007.087411. Epub 2008 Apr 15.

PMID:
18413443
9.

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept.

Halbig M, Horneff G.

Rheumatol Int. 2009 Dec;30(2):229-38. doi: 10.1007/s00296-009-0942-3.

PMID:
19449011
10.

Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N.

Rheumatol Int. 2012 Sep;32(9):2675-9. doi: 10.1007/s00296-011-2030-8. Epub 2011 Jul 26.

PMID:
21789614
11.

Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.

Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK.

J Rheumatol. 2007 May;34(5):1146-50. Epub 2007 Mar 1.

PMID:
17343318
12.

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M; All Departments of Rheumatology in Denmark..

Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227.

13.

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.

Arthritis Rheum. 2003 Apr;48(4):1093-101.

14.

Anaphylaxis to etanercept in two children with juvenile idiopathic arthritis.

Crayne CB, Gerhold K, Cron RQ.

J Clin Rheumatol. 2013 Apr;19(3):129-31. doi: 10.1097/RHU.0b013e318285f1e9. Review.

PMID:
23519173
15.

Etanercept and uveitis in patients with juvenile idiopathic arthritis.

Schmeling H, Horneff G.

Rheumatology (Oxford). 2005 Aug;44(8):1008-11. Epub 2005 Apr 26.

PMID:
15855187
16.

Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.

van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM.

J Rheumatol. 2011 Jul;38(7):1441-6. doi: 10.3899/jrheum.100809. Epub 2011 Apr 1.

PMID:
21459936
17.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Carter CT, Changolkar AK, Scott McKenzie R.

J Med Econ. 2012;15(2):332-9. doi: 10.3111/13696998.2011.649325. Epub 2012 Jan 6.

PMID:
22168788
18.

Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

19.

[Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].

Horneff G.

Z Rheumatol. 2010 Aug;69(6):516-26. doi: 10.1007/s00393-010-0655-8. Review. German.

PMID:
20532787
20.

Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab.

Katsicas MM, Russo RA.

Clin Rheumatol. 2009 Aug;28(8):985-8. doi: 10.1007/s10067-009-1162-7. Epub 2009 Mar 26.

PMID:
19322622

Supplemental Content

Support Center